Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis
about
Environmental enteropathy: critical implications of a poorly understood condition.Inflammasome activation contributes to interleukin-23 production in response to Clostridium difficile.Quantitative Fecal Lactoferrin as a Biomarker for Severe Clostridium difficile Infection in Hospitalized Patients.Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain.Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile.Clostridium difficile infection in patients with inflammatory bowel diseaseCalprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.Susceptibility of hamsters to Clostridium difficile isolates of differing toxinotype.Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kappa B site on its promoter.Clostridium difficile testing: after 20 years, still challenging.The systemic inflammatory response to Clostridium difficile infectionImpact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections.Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.Quantification of Clostridium difficile in antibiotic-associated-diarrhea patientsOutcomes in patients tested for Clostridium difficile toxins.Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure.Quantitative fecal lactoferrin in toxin-positive and toxin-negative Clostridium difficile specimens.MAPK-activated protein kinase 2 contributes to Clostridium difficile-associated inflammationPotential of lactoferrin to prevent antibiotic-induced Clostridium difficile infectionMarkers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.Environmental Enteric Dysfunction in Children.Elevated fecal calprotectin associates with adverse outcomes from Clostridium difficile infection in older adults.Colonic immunopathogenesis of Clostridium difficile infections.Antimicrobial peptides and colitis.Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity.Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.Recurrent Clostridium difficile Infection in Children: Patient Risk Factors and Markers of Intestinal Inflammation.Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.The P2Y6 receptor mediates Clostridium difficile toxin-induced CXCL8/IL-8 production and intestinal epithelial barrier dysfunction.Is Fecal Leukocyte Test a good predictor of Clostridium difficile associated diarrhea?Innate immune response and outcome of Clostridium difficile infection are dependent on fecal bacterial composition in the aged host.The role of toxins in Clostridium difficile infection.The ATP-P2X7 Signaling Axis Is an Essential Sentinel for Intracellular Clostridium difficile Pathogen-Induced Inflammasome Activation.Systemic Inflammatory Responses in Ulcerative Colitis Patients and Clostridium difficile Infection
P2860
Q24606211-AF57ED4B-4B33-4346-861C-F31AA1729FB0Q30300885-B1B41997-EEA1-4D5E-B7F5-F02DE1278C05Q30301297-CC372E74-891F-432D-B8DF-670B5858A265Q30429490-D1B5178C-1B32-4561-8E9A-9DA347C2DCCBQ30434665-8AA57480-C2FC-4608-958A-AEDFD94E7CD5Q33947432-E726FB02-4F97-47F7-BD66-A1D5F8DA1265Q34110399-3068CCD7-2C3B-4BE1-82B2-83709226E6F2Q34737968-BBD4CCF5-9109-4986-8B33-835DB9E81250Q34809257-36D3670A-1A3B-46D2-9C44-2E0F93222316Q35062641-F1E46079-3EF7-4CC4-BE69-4E74CD344B45Q35124315-DC73393B-014C-4049-A284-8800995DD2C2Q35139786-E81B3500-870E-4ACB-8082-857581E8334AQ35208564-94F35DCB-2C7B-4563-9191-43C72C448F0DQ35273806-CB7E4C18-1238-4629-9335-E641540C83D4Q36395224-5DBA299B-347F-4367-A755-1EA0FBED603FQ36396899-FB3948F1-FECF-47E4-B5EC-D152B63E83A6Q36506386-56380CD2-A1D3-412C-820A-8A08F0F4E5D1Q36646782-0882E45B-9C53-41A1-BD7C-31CA0F19AA32Q36684188-CD663499-14A9-4D36-B90E-E21608A3D81BQ36999988-C26978A4-F075-48AC-8E08-493BAC57F225Q37035829-8BC87860-81E6-4A43-B73E-DB41A0A542E8Q37037319-6D5DA95A-7D94-4D2C-9559-5FF132089616Q37109212-E60980D6-E00F-43CA-AFB8-906F6F89DEADQ37712845-9B0C6AA8-4577-40D5-82CF-606CC42427F2Q38040831-C5763530-FF5A-4730-9B31-7DC7EBD728DDQ38737485-35778C4F-28D5-49B2-9E00-85DB0BE47368Q40130108-8670B2BD-D9BD-4BF6-BD16-132E58C45725Q40408914-A06C2C08-08BC-4E07-8E4F-83556707209FQ41834229-9D6F5FBA-B642-47B7-9640-47A650D90351Q42020494-4EF506DA-6F91-41CC-A61B-563A4417F8ADQ42281148-604AC8C2-E834-4A10-9881-97ABABF31689Q45068991-23998911-C015-4BE8-BE99-E5A9A2DFC45AQ47734724-40281056-BAC0-4568-B02D-BCD8220CDC4CQ52332673-D4CD47FB-98DF-4F75-84A5-1A1DF3426271Q57177958-D54827EF-4F24-420A-B42A-022F9D8314F9
P2860
Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Fecal lactoferrin, interleukin ...... Clostridium difficile colitis
@ast
Fecal lactoferrin, interleukin ...... Clostridium difficile colitis
@en
type
label
Fecal lactoferrin, interleukin ...... Clostridium difficile colitis
@ast
Fecal lactoferrin, interleukin ...... Clostridium difficile colitis
@en
prefLabel
Fecal lactoferrin, interleukin ...... Clostridium difficile colitis
@ast
Fecal lactoferrin, interleukin ...... Clostridium difficile colitis
@en
P2093
P2860
P921
P1476
Fecal lactoferrin, interleukin ...... Clostridium difficile colitis
@en
P2093
C A Flores
R L Guerrant
T S Steiner
T T Pizarro
P2860
P304
P577
1997-11-01T00:00:00Z